CN Patent

CN111057021B — 均三嗪类化合物及其制备方法和用途

Assigned to China Pharmaceutical University · Expires 2023-05-23 · 3y expired

What this patent protects

本发明公开了一类均三嗪类化合物及其药学可接受的盐，实验证明，该类化合物可以通过抑制布鲁顿酪氨酸激酶Btk来治疗或预防与蛋白激酶活性相关的疾病如白血病、淋巴瘤。

USPTO Abstract

本发明公开了一类均三嗪类化合物及其药学可接受的盐，实验证明，该类化合物可以通过抑制布鲁顿酪氨酸激酶Btk来治疗或预防与蛋白激酶活性相关的疾病如白血病、淋巴瘤。

Drugs covered by this patent

Patent Metadata

Patent number: CN111057021B
Jurisdiction: CN
Classification: —
Expires: 2023-05-23
Drug substance claim: No
Drug product claim: No
Assignee: China Pharmaceutical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.